Market Research Logo

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016

Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Peripheral T-Cell Lymphomas (PTCL) - Pipeline Review, H2 2016’, provides an overview of the Peripheral T-Cell Lymphomas (PTCL) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral T-Cell Lymphomas (PTCL), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral T-Cell Lymphomas (PTCL) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

  • Certain sections in the report may be removed or altered based on the availability and relevance of data.


  • Scope
    • The report provides a snapshot of the global therapeutic landscape of Peripheral T-Cell Lymphomas (PTCL)
    • The report reviews pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL) by companies and universities/research institutes based on information derived from company and industry-specific sources
    • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    • The report reviews key players involved Peripheral T-Cell Lymphomas (PTCL) therapeutics and enlists all their major and minor projects
    • The report assesses Peripheral T-Cell Lymphomas (PTCL) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
    • The report summarizes all the dormant and discontinued pipeline projects
    • The report reviews latest news related to pipeline therapeutics for Peripheral T-Cell Lymphomas (PTCL)
    Reasons to buy
    • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    • Identify and understand important and diverse types of therapeutics under development for Peripheral T-Cell Lymphomas (PTCL)
    • Identify potential new clients or partners in the target demographic
    • Develop strategic initiatives by understanding the focus areas of leading companies
    • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
    • Devise corrective measures for pipeline projects by understanding Peripheral T-Cell Lymphomas (PTCL) pipeline depth and focus of Indication therapeutics
    • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


    Introduction
    Global Markets Direct Report Coverage
    Peripheral T-Cell Lymphomas (PTCL) Overview
    Therapeutics Development
    Pipeline Products for Peripheral T-Cell Lymphomas (PTCL) - Overview
    Peripheral T-Cell Lymphomas (PTCL) - Therapeutics under Development by Companies
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline Products Glance
    Late Stage Products
    Clinical Stage Products
    Early Stage Products
    Peripheral T-Cell Lymphomas (PTCL) - Products under Development by Companies
    Peripheral T-Cell Lymphomas (PTCL) - Companies Involved in Therapeutics Development
    AB Science SA
    Affimed GmbH
    arGEN-X BV
    Bayer AG
    Boehringer Ingelheim GmbH
    Celgene Corporation
    CerRx, Inc.
    Chipscreen Biosciences Ltd
    CSPC Pharmaceutical Group Limited
    Eisai Co., Ltd.
    Genosco
    Incyte Corporation
    Japan Tobacco Inc.
    Johnson & Johnson
    Mundipharma International Ltd
    Ono Pharmaceutical Co., Ltd.
    Onxeo SA
    Pfizer Inc.
    Pharma Mar, S.A.
    Portola Pharmaceuticals, Inc.
    Rhizen Pharmaceuticals S.A.
    Seattle Genetics, Inc.
    Solasia Pharma K.K.
    Spectrum Pharmaceuticals, Inc.
    Peripheral T-Cell Lymphomas (PTCL) - Therapeutics Assessment
    Assessment by Monotherapy Products
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Drug Profiles
    AFM-13 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ARGX-110 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    belinostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    brentuximab vedotin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Cellular Immunotherapy to Target CD7 for Relapsed and Refractory Leukemia and Lymphoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    cerdulatinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    copanlisib hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    darinaparsin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    denileukin diftitox - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    enasidenib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fenretinide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    forodesine hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ICG-122 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lenalidomide - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    masitinib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MEDI-570 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mitoxantrone hydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nivolumab - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NL-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    plitidepsin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pralatrexate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    romidepsin - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RP-6530 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ruxolitinib phosphate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SH-7129 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit SYK for Diffuse Large B-Cell Lymphoma and Peripheral T-Cell Lymphoma - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    temsirolimus - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TGR-1202 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tipifarnib - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    tucidinostat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    volasertib trihydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects
    Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products
    Peripheral T-Cell Lymphomas (PTCL) - Product Development Milestones
    Featured News & Press Releases
    Aug 16, 2016: CAR T-cells Targeting the CD4 Protein Granted FDA Orphan Drug Designation
    Aug 11, 2016: CAR T-cells Targeting the CD4 Protein Granted Orphan Drug Designation for the Treatment of Peripheral T-cell Lymphoma
    Jun 14, 2016: PharmaMar Announces the Start of a Pivotal Study With plitidepsin in angioimmunoblastic T-cell lymphoma
    Jun 02, 2016: Onxeo Announces Development of Beleodaq Oral Formulation Opening New Opportunities for Its HDAC Inhibitor
    Mar 28, 2016: Solasia Initiates Phase 2 Study of Darinaparsin (SP-02) for Peripheral T-Cell Lymphoma
    Dec 22, 2015: Huya Bioscience International Announces Orphan Drug Designation For HBI-8000 In Japan
    Dec 07, 2015: Seattle Genetics Highlights ADCETRIS Data Presentations in Frontline Non-Hodgkin Lymphoma at ASH 2015
    Dec 06, 2015: Spectrum Pharmaceuticals and Onxeo Announce Complete Response in 67% of Patients with Peripheral T-Cell Lymphoma in Combination of Belinostat and Standard CHOP
    Nov 09, 2015: Onxeo Reports Initial Results of Phase 1 Trial Evaluating Belinostat in Combination with CHOP in Peripheral T-cell Lymphoma
    Sep 30, 2015: Kura Oncology Initiates Phase 2 Study of Tipifarnib in Peripheral T-cell Lymphoma
    Jun 23, 2015: Beleodaq (belinostat) pivotal BELIEF study results published in the Journal of Clinical Oncology
    May 27, 2015: AB Science: Phase 2 with masitinib in peripheral T-cell lymphoma accelerated into phase 3
    Jan 12, 2015: HUYA Bioscience International Announces Regulatory Approval Of Chidamide, The First Selective HDAC Inhibitor In China
    Jan 09, 2015: Chipscreen Biosciences Announces CFDA Approval of Chidamide (Epidaza) for PTCLs in China
    Jan 08, 2015: HUYA Bioscience International Is The First To Leverage Tripartite Cooperation
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer
    List of Tables
    Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016
    Number of Products under Development by Companies, H2 2016
    Number of Products under Development by Companies, H2 2016 (Contd..1)
    Comparative Analysis by Late Stage Development, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Development, H2 2016
    Products under Development by Companies, H2 2016
    Products under Development by Companies, H2 2016 (Contd..1)
    Products under Development by Companies, H2 2016 (Contd..2)
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by AB Science SA, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Affimed GmbH , H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by arGEN-X BV, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Bayer AG, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Celgene Corporation, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CerRx, Inc., H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Chipscreen Biosciences Ltd, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Eisai Co., Ltd., H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Genosco, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Incyte Corporation, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Japan Tobacco Inc., H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Johnson & Johnson, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Mundipharma International Ltd, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Onxeo SA, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pfizer Inc., H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Pharma Mar, S.A., H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Rhizen Pharmaceuticals S.A., H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Seattle Genetics, Inc., H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Solasia Pharma K.K., H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Stage and Target, H2 2016
    Number of Products by Stage and Mechanism of Action, H2 2016
    Number of Products by Stage and Route of Administration, H2 2016
    Number of Products by Stage and Molecule Type, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Dormant Projects, H2 2016
    Peripheral T-Cell Lymphomas (PTCL) - Discontinued Products, H2 2016
    List of Figures
    Number of Products under Development for Peripheral T-Cell Lymphomas (PTCL), H2 2016
    Number of Products under Development by Companies, H2 2016
    Comparative Analysis by Clinical Stage Development, H2 2016
    Comparative Analysis by Early Stage Products, H2 2016
    Assessment by Monotherapy Products, H2 2016
    Number of Products by Top 10 Targets, H2 2016
    Number of Products by Stage and Top 10 Targets, H2 2016
    Number of Products by Top 10 Mechanism of Actions, H2 2016
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
    Number of Products by Routes of Administration, H2 2016
    Number of Products by Stage and Routes of Administration, H2 2016
    Number of Products by Molecule Types, H2 2016
    Number of Products by Stage and Molecule Types, H2 2016

    Download our eBook: How to Succeed Using Market Research

    Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

    Download eBook

    Share this report